Literature DB >> 2041853

Exchange transfusion of a patient with fulminant Lassa fever.

D Cummins1, D Bennett, S J Machin.   

Abstract

We report a patient with fulminant Lassa fever who responded dramatically to a 2.5-litre exchange transfusion of whole blood. On admission he was semicomatose with facial oedema and oral haemorrhage; his platelets showed markedly depressed aggregation to ADP; and his plasma inhibited the aggregation responses of normal platelets in vitro. Exchange transfusion resulted in rapid clinical improvement, recovery of platelet function, and disappearance of platelet-inhibitory activity in plasma. The patient died 2 weeks later from an acute encephalopathy. His initial response was sufficiently impressive to suggest that further evaluation of this therapeutic approach is justified in selected patients with overwhelming Lassa virus infection.

Entities:  

Mesh:

Year:  1991        PMID: 2041853      PMCID: PMC2398981          DOI: 10.1136/pgmj.67.784.193

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  8 in total

1.  Plasma from patients with severe Lassa fever profoundly modulates f-met-leu-phe induced superoxide generation in neutrophils.

Authors:  P J Roberts; D Cummins; A L Bainton; K J Walshe; S P Fisher-Hoch; J B McCormick; J G Gribben; S J Machin; D C Linch
Journal:  Br J Haematol       Date:  1989-10       Impact factor: 6.998

2.  A case-control study of the clinical diagnosis and course of Lassa fever.

Authors:  J B McCormick; I J King; P A Webb; K M Johnson; R O'Sullivan; E S Smith; S Trippel; T C Tong
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

3.  Safe intensive-care management of a severe case of Lassa fever with simple barrier nursing techniques.

Authors:  S P Fisher-Hoch; M E Price; R B Craven; F M Price; D N Forthall; D R Sasso; S M Scott; J B McCormick
Journal:  Lancet       Date:  1985-11-30       Impact factor: 79.321

4.  The use of Lassa fever convalescent plasma in Nigeria.

Authors:  J D Frame; G P Verbrugge; R G Gill; L Pinneo
Journal:  Trans R Soc Trop Med Hyg       Date:  1984       Impact factor: 2.184

5.  Pathologic and virologic study of fatal Lassa fever in man.

Authors:  D H Walker; J B McCormick; K M Johnson; P A Webb; G Komba-Kono; L H Elliott; J J Gardner
Journal:  Am J Pathol       Date:  1982-06       Impact factor: 4.307

6.  Lassa fever. Effective therapy with ribavirin.

Authors:  J B McCormick; I J King; P A Webb; C L Scribner; R B Craven; K M Johnson; L H Elliott; R Belmont-Williams
Journal:  N Engl J Med       Date:  1986-01-02       Impact factor: 91.245

7.  Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease.

Authors:  E Leifer; D J Gocke; H Bourne
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

8.  A plasma inhibitor of platelet aggregation in patients with Lassa fever.

Authors:  D Cummins; S P Fisher-Hoch; K J Walshe; I J Mackie; J B McCormick; D Bennett; G Perez; B Farrar; S J Machin
Journal:  Br J Haematol       Date:  1989-08       Impact factor: 6.998

  8 in total
  2 in total

1.  Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.

Authors:  Robert W Cross; Chad E Mire; Luis M Branco; Joan B Geisbert; Megan M Rowland; Megan L Heinrich; Augustine Goba; Mambu Momoh; Donald S Grant; Mohamed Fullah; Sheik Humarr Khan; James E Robinson; Thomas W Geisbert; Robert F Garry
Journal:  Antiviral Res       Date:  2016-08-13       Impact factor: 5.970

2.  Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.

Authors:  Laura Merson; Josephine Bourner; Sulaiman Jalloh; Astrid Erber; Alex Paddy Salam; Antoine Flahault; Piero L Olliaro
Journal:  PLoS Negl Trop Dis       Date:  2021-09-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.